WASHINGTON--Samuel Broder, MD, head of the National Cancer Institute
(NCI) for the past 5 years, says that he will resign his post
in April of this year. He will join IVAX Corporation (Miami),
a manufacturer of generic drugs and IV drug delivery devices,
where he plans to work on developing new drugs.
Dr. Broder first joined the NCI in 1972 as a researcher. He was
the leader of a group that discovered the therapeutic benefits
of the antiretroviral agent zidovudine (Retrovir, AZT) in 1985.